Engaging Adult Patients With C3GN: Shared Decision-Making at the Crossroads of Complement-Targeted Therapy
Sayna Norouzi, MD
Extra Innings – Sustaining Victory Beyond the First Game
J.A. Randy Englert, MD, FACC
Matthew Malachowski, Pharm. D., MHA
Turning the Double Play – Comprehensive Secondary Prevention
Translating the Latest KDIGO Guidelines Into Practice: IV Iron Therapy in Patients With Non–Dialysis-Dependent CKD
Patrick Rossignol, MD, PhD
Julio Núñez, MD, PhD
Vous prescrivez uniquement des antihistaminiques pour traiter les patients atteints de Pa-MRC ? Il est temps de revoir votre approche !
Antoine Lanot, MD, PhD
Gil Yosipovitch, MD
Transforming Care in Pediatric Patients With C3 Glomerulopathy: Targeting C3 at the Source
Richard Lafayette, MD, FACP
Ankana Daga, MD
Stuck on Antihistamines for Managing Patients With CKD-aP? Time to Reconsider!
When ß-Blockers Fall Short in oHCM: Time for a New Approach?
Ahmad Masri, MD, MS
Anjali Owens, MD
Modern Obstructive HCM Care: From Unmet Needs to Individualized Myosin Inhibitor Therapy
Cracking the Code of Obstruction: Unmet Needs in oHCM
Michael Nassif, MD, MSc
From Beta-Blockers to Myosin Inhibitors: Initial Decision-Making in Obstructive HCM
Redefining oHCM Care: Efficacy and Safety of Myosin Inhibitors
From Evidence to Action: Integrating Emerging Myosin Inhibitors Into oHCM Treatment Plans
Case-Based Approach: Managing Hyperkalemia in Patients With CKD and Heart Failure
Ellie Kelepouris, MD, FACP, FAHA
Nihar R. Desai, MD, MPH
The Overlooked Valve: Why Women With Aortic Stenosis Fall Through the Cracks
Pam R. Taub, MD, FACC, FASPC
The Patient-Clinician Connection in Managing CKD-aP
James Burton, DM, FRCP
Lucio Manenti, MD, PhD